Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
第一作者:
Peter,Ströberg
第一单位:
ED-kliniken, Långgatan 18, 541 30 Skövde, Sweden. peter.stroeberg@telia.com
作者:
医学主题词
3',5'-环GMP磷酸二酯酶类(3',5'-Cyclic-GMP Phosphodiesterases);投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);咔啉类(Carbolines);环核苷酸磷酸二酯酶类, 5型(Cyclic Nucleotide Phosphodiesterases, Type 5);药物处方(Drug Prescriptions);药物疗法, 联合(Drug Therapy, Combination);勃起功能障碍(Erectile Dysfunction);可行性研究(Feasibility Studies);随访研究(Follow-Up Studies);人类(Humans);咪唑类(Imidazoles);男(雄)性(Male);中年人(Middle Aged);病人满意度(Patient Satisfaction);磷酸二酯酶抑制剂(Phosphodiesterase Inhibitors);磷酸二酯水解酶类(Phosphoric Diester Hydrolases);哌嗪类(Piperazines);嘌呤类(Purines);回顾性研究(Retrospective Studies);砜类(Sulfones);治疗结果(Treatment Outcome);三嗪类(Triazines)
DOI
10.1016/j.eururo.2006.02.032
PMID
16564126
发布时间
2015-11-19
- 浏览6
European urology
900-7; discussion 907页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



